No Data
No Data
Express News | Palisade Bio Shares Are Trading Higher After the Company Announced the Completion of the First Good Manufacturing Practice Batch of Its Drug Substance PALI-2108 and Is on Track to Commence Its Phase 1 Human Clinical Study
Express News | Palisade Bio Completes Pivotal Nonclinical Studies And Formulates Enteric-Coated Tablets Of PALI-2108; On Track To Commence Phase 1 Clinical Study For Moderate-To-Severe Ulcerative Colitis By Year End
Express News | Palisade Bio: On Track to Start Phase 1 Human Clinical Study of Pali-2108 for Treatment of Moderate-to-Severe Ulcerative Colitis Before Year End
Express News | Palisade Bio Inc: Completed Murine and Non-Murine Pivotal Nonclinical Studies Using Gmp Pali-2108 Drug Substance
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substanceCompany has successfully formulated enteric-coated tablets of PALI-2108 and has
Palisade Bio to Participate in the Virtual Investor Closing Bell Series
Live video webcast on Wednesday, June 26th at 4:00 PM ET Carlsbad, CA, June 24, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), biopharmaceutical company focused on developi
No Data